The clinical efficacy of PCSK9-i was shown in previous studies [19, 20]; in particular, the reduction of LDL-C and ASCVD by PCSK9-i was ≃50–60% and 15%, respectively. This evidence concerns the gene PCSK9 and atherosclerosis.